Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HZNP Horizon Therapeutics Public (HZNP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Horizon Therapeutics Public Stock (NASDAQ:HZNP) 30 days 90 days 365 days Advanced Chart Ad Chaikin AnalyticsIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is making headlines for last week's new earnings report – which revealed the AI juggernaut nearly doubled their profits in the last year alone.A 50-year Wall Street veteran gives his answer Nvidia, right here... Get HZNP alerts:Sign Up Key Stats Today's Range$116.30▼$116.3050-Day Range$112.60▼$116.3052-Week Range$60.03▼$116.38VolumeN/AAverage Volume2.50 million shsMarket Capitalization$26.63 billionP/E Ratio62.19Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewHorizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.Read More… Is NVDA a sell? Buy this stock instead before Dec 3 (Ad)After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is making headlines for last week's new earnings report – which revealed the AI juggernaut nearly doubled their profits in the last year alone.A 50-year Wall Street veteran gives his answer Nvidia, right here... Horizon Therapeutics Public Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks42nd Percentile Overall ScoreHZNP MarketRank™: Horizon Therapeutics Public scored higher than 42% of companies evaluated by MarketBeat, and ranked 676th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Horizon Therapeutics Public. Earnings and Valuation3.1 / 5Proj. Earnings Growth35.08% Earnings GrowthEarnings for Horizon Therapeutics Public are expected to grow by 35.08% in the coming year, from $4.19 to $5.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Horizon Therapeutics Public is 62.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Horizon Therapeutics Public is 62.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 90.38.Price to Earnings Growth RatioHorizon Therapeutics Public has a PEG Ratio of 3.96. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHorizon Therapeutics Public has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HZNP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHorizon Therapeutics Public does not currently pay a dividend.Dividend GrowthHorizon Therapeutics Public does not have a long track record of dividend growth. Sustainability and ESG3.2 / 5Environmental Score-2.61 Short InterestThere is no current short interest data available for HZNP. News and Social Media0.6 / 5News SentimentN/A Search Interest18 people have searched for HZNP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Horizon Therapeutics Public insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Horizon Therapeutics Public is held by insiders.Percentage Held by Institutions80.37% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Horizon Therapeutics Public's insider trading history. Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address HZNP Stock News HeadlinesHorizon Therapeutics Public Lim (HZNP)April 27, 2024 | finance.yahoo.com5 Biotech Acquisition Targets To Accumulate In 2024December 21, 2023 | seekingalpha.comEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.November 27, 2024 | ProsperityPub (Ad)Nasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business CombinationNovember 16, 2023 | msn.comHorizon Therapeutics cut jobs in Deerfield after Amgen acquisitionOctober 24, 2023 | chicago.suntimes.com350 Horizon Therapeutics workers to be laid off, mostly from Deerfield offices, following acquisition by AmgenOctober 24, 2023 | msn.comRule 17(e) Announcement - Horizon Therapeutics plcOctober 6, 2023 | finance.yahoo.com3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in OctoberOctober 5, 2023 | stocknews.comSee More Headlines HZNP Stock Analysis - Frequently Asked Questions How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.08. Horizon Therapeutics Public's revenue for the quarter was up 7.8% compared to the same quarter last year. Does Horizon Therapeutics Public have any subsidiaries? Horizon Therapeutics Public subsidiaries include Viela Bio Inc., Curzion Pharmaceuticals Inc., River Vision Development Corp., Raptor Pharmaceuticals, Hyperion Therapeutics, Vidara Therapeutics, Horizon Medicines LLC, and others. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some other companies that Horizon Therapeutics Public investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), PayPal (PYPL), Tesla (TSLA), Netflix (NFLX) and Bristol-Myers Squibb (bmy). Company Calendar Last Earnings8/08/2023Today11/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees2,115Year Founded2008Profitability EPS (Most Recent Fiscal Year)$1.87 Trailing P/E Ratio62.19 Forward P/E Ratio27.76 P/E Growth3.96Net Income$521.48 million Net Margins12.02% Pretax Margin12.18% Return on Equity20.46% Return on Assets11.52% Debt Debt-to-Equity Ratio0.48 Current Ratio4.27 Quick Ratio4.09 Sales & Book Value Annual Sales$3.63 billion Price / Sales7.34 Cash Flow$7.05 per share Price / Cash Flow16.49 Book Value$22.38 per share Price / Book5.20Miscellaneous Outstanding Shares228,990,000Free Float223,957,000Market Cap$26.63 billion OptionableOptionable Beta1.03 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:HZNP) was last updated on 11/27/2024 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Horizon Therapeutics Public With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.